Global Neuroendocrine Carcinoma Market Growth (Status and Outlook) 2022-2028

January 2022 | 104 pages | ID: GE545FBB7ED4EN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

As the global economy mends, the 2021 growth of Neuroendocrine Carcinoma will have significant change from previous year. According to our (LP Information) latest study, the global Neuroendocrine Carcinoma market size is USD million in 2022 from USD million in 2021, with a change of % between 2021 and 2022. The global Neuroendocrine Carcinoma market size will reach USD million in 2028, growing at a CAGR of % over the analysis period.

The United States Neuroendocrine Carcinoma market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Neuroendocrine Carcinoma market, reaching US$ million by the year 2028. As for the Europe Neuroendocrine Carcinoma landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.

Global main Neuroendocrine Carcinoma players cover Pfizer, Novartis, Chiasma, and Ipsen, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.

This report presents a comprehensive overview, market shares, and growth opportunities of Neuroendocrine Carcinoma market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.

• Chemotherapy
• Somatostatin Analogs
• Targeted Therapy

Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.

• Hospital
• Clinics
• Oncology Centres
• Ambulatory Surgery Centres

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.

• Pfizer
• Novartis
• Chiasma
• Ipsen
• Abbvie
• Valeant
• Jubilant
• Teva
• F.Hoffmann-La Roche
• Advanced Accelerator
• Mateon
• Lexicon

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global Neuroendocrine Carcinoma Market Size 2017-2028
  2.1.2 Neuroendocrine Carcinoma Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Neuroendocrine Carcinoma Segment by Type
  2.2.1 Chemotherapy
  2.2.2 Somatostatin Analogs
  2.2.3 Targeted Therapy
2.3 Neuroendocrine Carcinoma Market Size by Type
  2.3.1 Neuroendocrine Carcinoma Market Size CAGR by Type (2017 VS 2022 VS 2028)
  2.3.2 Global Neuroendocrine Carcinoma Market Size Market Share by Type (2017-2022)
2.4 Neuroendocrine Carcinoma Segment by Application
  2.4.1 Hospital
  2.4.2 Clinics
  2.4.3 Oncology Centres
  2.4.4 Ambulatory Surgery Centres
2.5 Neuroendocrine Carcinoma Market Size by Application
  2.5.1 Neuroendocrine Carcinoma Market Size CAGR by Application (2017 VS 2022 VS 2028)
  2.5.2 Global Neuroendocrine Carcinoma Market Size Market Share by Application (2017-2022)

3 NEUROENDOCRINE CARCINOMA MARKET SIZE BY PLAYER

3.1 Neuroendocrine Carcinoma Market Size Market Share by Players
  3.1.1 Global Neuroendocrine Carcinoma Revenue by Players (2020-2022)
  3.1.2 Global Neuroendocrine Carcinoma Revenue Market Share by Players (2020-2022)
3.2 Global Neuroendocrine Carcinoma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 NEUROENDOCRINE CARCINOMA BY REGIONS

4.1 Neuroendocrine Carcinoma Market Size by Regions (2017-2022)
4.2 Americas Neuroendocrine Carcinoma Market Size Growth (2017-2022)
4.3 APAC Neuroendocrine Carcinoma Market Size Growth (2017-2022)
4.4 Europe Neuroendocrine Carcinoma Market Size Growth (2017-2022)
4.5 Middle East & Africa Neuroendocrine Carcinoma Market Size Growth (2017-2022)

5 AMERICAS

5.1 Americas Neuroendocrine Carcinoma Market Size by Country (2017-2022)
5.2 Americas Neuroendocrine Carcinoma Market Size by Type (2017-2022)
5.3 Americas Neuroendocrine Carcinoma Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC Neuroendocrine Carcinoma Market Size by Region (2017-2022)
6.2 APAC Neuroendocrine Carcinoma Market Size by Type (2017-2022)
6.3 APAC Neuroendocrine Carcinoma Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe Neuroendocrine Carcinoma by Country (2017-2022)
7.2 Europe Neuroendocrine Carcinoma Market Size by Type (2017-2022)
7.3 Europe Neuroendocrine Carcinoma Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Neuroendocrine Carcinoma by Region (2017-2022)
8.2 Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2017-2022)
8.3 Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL NEUROENDOCRINE CARCINOMA MARKET FORECAST

10.1 Global Neuroendocrine Carcinoma Forecast by Regions (2023-2028)
  10.1.1 Global Neuroendocrine Carcinoma Forecast by Regions (2023-2028)
  10.1.2 Americas Neuroendocrine Carcinoma Forecast
  10.1.3 APAC Neuroendocrine Carcinoma Forecast
  10.1.4 Europe Neuroendocrine Carcinoma Forecast
  10.1.5 Middle East & Africa Neuroendocrine Carcinoma Forecast
10.2 Americas Neuroendocrine Carcinoma Forecast by Country (2023-2028)
  10.2.1 United States Neuroendocrine Carcinoma Market Forecast
  10.2.2 Canada Neuroendocrine Carcinoma Market Forecast
  10.2.3 Mexico Neuroendocrine Carcinoma Market Forecast
  10.2.4 Brazil Neuroendocrine Carcinoma Market Forecast
10.3 APAC Neuroendocrine Carcinoma Forecast by Region (2023-2028)
  10.3.1 China Neuroendocrine Carcinoma Market Forecast
  10.3.2 Japan Neuroendocrine Carcinoma Market Forecast
  10.3.3 Korea Neuroendocrine Carcinoma Market Forecast
  10.3.4 Southeast Asia Neuroendocrine Carcinoma Market Forecast
  10.3.5 India Neuroendocrine Carcinoma Market Forecast
  10.3.6 Australia Neuroendocrine Carcinoma Market Forecast
10.4 Europe Neuroendocrine Carcinoma Forecast by Country (2023-2028)
  10.4.1 Germany Neuroendocrine Carcinoma Market Forecast
  10.4.2 France Neuroendocrine Carcinoma Market Forecast
  10.4.3 UK Neuroendocrine Carcinoma Market Forecast
  10.4.4 Italy Neuroendocrine Carcinoma Market Forecast
  10.4.5 Russia Neuroendocrine Carcinoma Market Forecast
10.5 Middle East & Africa Neuroendocrine Carcinoma Forecast by Region (2023-2028)
  10.5.1 Egypt Neuroendocrine Carcinoma Market Forecast
  10.5.2 South Africa Neuroendocrine Carcinoma Market Forecast
  10.5.3 Israel Neuroendocrine Carcinoma Market Forecast
  10.5.4 Turkey Neuroendocrine Carcinoma Market Forecast
  10.5.5 GCC Countries Neuroendocrine Carcinoma Market Forecast
10.6 Global Neuroendocrine Carcinoma Forecast by Type (2023-2028)
10.7 Global Neuroendocrine Carcinoma Forecast by Application (2023-2028)

11 KEY PLAYERS ANALYSIS

11.1 Pfizer
  11.1.1 Pfizer Company Information
  11.1.2 Pfizer Neuroendocrine Carcinoma Product Offered
  11.1.3 Pfizer Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.1.4 Pfizer Main Business Overview
  11.1.5 Pfizer Latest Developments
11.2 Novartis
  11.2.1 Novartis Company Information
  11.2.2 Novartis Neuroendocrine Carcinoma Product Offered
  11.2.3 Novartis Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.2.4 Novartis Main Business Overview
  11.2.5 Novartis Latest Developments
11.3 Chiasma
  11.3.1 Chiasma Company Information
  11.3.2 Chiasma Neuroendocrine Carcinoma Product Offered
  11.3.3 Chiasma Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.3.4 Chiasma Main Business Overview
  11.3.5 Chiasma Latest Developments
11.4 Ipsen
  11.4.1 Ipsen Company Information
  11.4.2 Ipsen Neuroendocrine Carcinoma Product Offered
  11.4.3 Ipsen Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.4.4 Ipsen Main Business Overview
  11.4.5 Ipsen Latest Developments
11.5 Abbvie
  11.5.1 Abbvie Company Information
  11.5.2 Abbvie Neuroendocrine Carcinoma Product Offered
  11.5.3 Abbvie Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.5.4 Abbvie Main Business Overview
  11.5.5 Abbvie Latest Developments
11.6 Valeant
  11.6.1 Valeant Company Information
  11.6.2 Valeant Neuroendocrine Carcinoma Product Offered
  11.6.3 Valeant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.6.4 Valeant Main Business Overview
  11.6.5 Valeant Latest Developments
11.7 Jubilant
  11.7.1 Jubilant Company Information
  11.7.2 Jubilant Neuroendocrine Carcinoma Product Offered
  11.7.3 Jubilant Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.7.4 Jubilant Main Business Overview
  11.7.5 Jubilant Latest Developments
11.8 Teva
  11.8.1 Teva Company Information
  11.8.2 Teva Neuroendocrine Carcinoma Product Offered
  11.8.3 Teva Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.8.4 Teva Main Business Overview
  11.8.5 Teva Latest Developments
11.9 F.Hoffmann-La Roche
  11.9.1 F.Hoffmann-La Roche Company Information
  11.9.2 F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Offered
  11.9.3 F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.9.4 F.Hoffmann-La Roche Main Business Overview
  11.9.5 F.Hoffmann-La Roche Latest Developments
11.10 Advanced Accelerator
  11.10.1 Advanced Accelerator Company Information
  11.10.2 Advanced Accelerator Neuroendocrine Carcinoma Product Offered
  11.10.3 Advanced Accelerator Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.10.4 Advanced Accelerator Main Business Overview
  11.10.5 Advanced Accelerator Latest Developments
11.11 Mateon
  11.11.1 Mateon Company Information
  11.11.2 Mateon Neuroendocrine Carcinoma Product Offered
  11.11.3 Mateon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.11.4 Mateon Main Business Overview
  11.11.5 Mateon Latest Developments
11.12 Lexicon
  11.12.1 Lexicon Company Information
  11.12.2 Lexicon Neuroendocrine Carcinoma Product Offered
  11.12.3 Lexicon Neuroendocrine Carcinoma Revenue, Gross Margin and Market Share (2020-2022)
  11.12.4 Lexicon Main Business Overview
  11.12.5 Lexicon Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Neuroendocrine Carcinoma Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Chemotherapy
Table 3. Major Players of Somatostatin Analogs
Table 4. Major Players of Targeted Therapy
Table 5. Neuroendocrine Carcinoma Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 6. Global Neuroendocrine Carcinoma Market Size by Type (2017-2022) & ($ Millions)
Table 7. Global Neuroendocrine Carcinoma Market Size Market Share by Type (2017-2022)
Table 8. Neuroendocrine Carcinoma Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 9. Global Neuroendocrine Carcinoma Market Size by Application (2017-2022) & ($ Millions)
Table 10. Global Neuroendocrine Carcinoma Market Size Market Share by Application (2017-2022)
Table 11. Global Neuroendocrine Carcinoma Revenue by Players (2020-2022) & ($ Millions)
Table 12. Global Neuroendocrine Carcinoma Revenue Market Share by Player (2020-2022)
Table 13. Neuroendocrine Carcinoma Key Players Head office and Products Offered
Table 14. Neuroendocrine Carcinoma Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Neuroendocrine Carcinoma Market Size by Regions 2017-2022 & ($ Millions)
Table 18. Global Neuroendocrine Carcinoma Market Size Market Share by Regions (2017-2022)
Table 19. Americas Neuroendocrine Carcinoma Market Size by Country (2017-2022) & ($ Millions)
Table 20. Americas Neuroendocrine Carcinoma Market Size Market Share by Country (2017-2022)
Table 21. Americas Neuroendocrine Carcinoma Market Size by Type (2017-2022) & ($ Millions)
Table 22. Americas Neuroendocrine Carcinoma Market Size Market Share by Type (2017-2022)
Table 23. Americas Neuroendocrine Carcinoma Market Size by Application (2017-2022) & ($ Millions)
Table 24. Americas Neuroendocrine Carcinoma Market Size Market Share by Application (2017-2022)
Table 25. APAC Neuroendocrine Carcinoma Market Size by Region (2017-2022) & ($ Millions)
Table 26. APAC Neuroendocrine Carcinoma Market Size Market Share by Region (2017-2022)
Table 27. APAC Neuroendocrine Carcinoma Market Size by Type (2017-2022) & ($ Millions)
Table 28. APAC Neuroendocrine Carcinoma Market Size Market Share by Type (2017-2022)
Table 29. APAC Neuroendocrine Carcinoma Market Size by Application (2017-2022) & ($ Millions)
Table 30. APAC Neuroendocrine Carcinoma Market Size Market Share by Application (2017-2022)
Table 31. Europe Neuroendocrine Carcinoma Market Size by Country (2017-2022) & ($ Millions)
Table 32. Europe Neuroendocrine Carcinoma Market Size Market Share by Country (2017-2022)
Table 33. Europe Neuroendocrine Carcinoma Market Size by Type (2017-2022) & ($ Millions)
Table 34. Europe Neuroendocrine Carcinoma Market Size Market Share by Type (2017-2022)
Table 35. Europe Neuroendocrine Carcinoma Market Size by Application (2017-2022) & ($ Millions)
Table 36. Europe Neuroendocrine Carcinoma Market Size Market Share by Application (2017-2022)
Table 37. Middle East & Africa Neuroendocrine Carcinoma Market Size by Region (2017-2022) & ($ Millions)
Table 38. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Region (2017-2022)
Table 39. Middle East & Africa Neuroendocrine Carcinoma Market Size by Type (2017-2022) & ($ Millions)
Table 40. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Type (2017-2022)
Table 41. Middle East & Africa Neuroendocrine Carcinoma Market Size by Application (2017-2022) & ($ Millions)
Table 42. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Application (2017-2022)
Table 43. Key Market Drivers & Growth Opportunities of Neuroendocrine Carcinoma
Table 44. Key Market Challenges & Risks of Neuroendocrine Carcinoma
Table 45. Key Industry Trends of Neuroendocrine Carcinoma
Table 46. Global Neuroendocrine Carcinoma Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 47. Global Neuroendocrine Carcinoma Market Size Market Share Forecast by Regions (2023-2028)
Table 48. Global Neuroendocrine Carcinoma Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 49. Global Neuroendocrine Carcinoma Market Size Market Share Forecast by Type (2023-2028)
Table 50. Global Neuroendocrine Carcinoma Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 51. Global Neuroendocrine Carcinoma Market Size Market Share Forecast by Application (2023-2028)
Table 52. Pfizer Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 53. Pfizer Neuroendocrine Carcinoma Product Offered
Table 54. Pfizer Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 55. Pfizer Main Business
Table 56. Pfizer Latest Developments
Table 57. Novartis Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 58. Novartis Neuroendocrine Carcinoma Product Offered
Table 59. Novartis Main Business
Table 60. Novartis Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 61. Novartis Latest Developments
Table 62. Chiasma Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 63. Chiasma Neuroendocrine Carcinoma Product Offered
Table 64. Chiasma Main Business
Table 65. Chiasma Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 66. Chiasma Latest Developments
Table 67. Ipsen Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 68. Ipsen Neuroendocrine Carcinoma Product Offered
Table 69. Ipsen Main Business
Table 70. Ipsen Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 71. Ipsen Latest Developments
Table 72. Abbvie Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 73. Abbvie Neuroendocrine Carcinoma Product Offered
Table 74. Abbvie Main Business
Table 75. Abbvie Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 76. Abbvie Latest Developments
Table 77. Valeant Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 78. Valeant Neuroendocrine Carcinoma Product Offered
Table 79. Valeant Main Business
Table 80. Valeant Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 81. Valeant Latest Developments
Table 82. Jubilant Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 83. Jubilant Neuroendocrine Carcinoma Product Offered
Table 84. Jubilant Main Business
Table 85. Jubilant Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 86. Jubilant Latest Developments
Table 87. Teva Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 88. Teva Neuroendocrine Carcinoma Product Offered
Table 89. Teva Main Business
Table 90. Teva Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 91. Teva Latest Developments
Table 92. F.Hoffmann-La Roche Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 93. F.Hoffmann-La Roche Neuroendocrine Carcinoma Product Offered
Table 94. F.Hoffmann-La Roche Main Business
Table 95. F.Hoffmann-La Roche Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 96. F.Hoffmann-La Roche Latest Developments
Table 97. Advanced Accelerator Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 98. Advanced Accelerator Neuroendocrine Carcinoma Product Offered
Table 99. Advanced Accelerator Main Business
Table 100. Advanced Accelerator Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 101. Advanced Accelerator Latest Developments
Table 102. Mateon Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 103. Mateon Neuroendocrine Carcinoma Product Offered
Table 104. Mateon Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 105. Mateon Main Business
Table 106. Mateon Latest Developments
Table 107. Lexicon Details, Company Type, Neuroendocrine Carcinoma Area Served and Its Competitors
Table 108. Lexicon Neuroendocrine Carcinoma Product Offered
Table 109. Lexicon Main Business
Table 110. Lexicon Neuroendocrine Carcinoma Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 111. Lexicon Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. Neuroendocrine Carcinoma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Neuroendocrine Carcinoma Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Neuroendocrine Carcinoma Market Size Market Share by Type in 2021
Figure 7. Neuroendocrine Carcinoma in Hospital
Figure 8. Global Neuroendocrine Carcinoma Market: Hospital (2017-2022) & ($ Millions)
Figure 9. Neuroendocrine Carcinoma in Clinics
Figure 10. Global Neuroendocrine Carcinoma Market: Clinics (2017-2022) & ($ Millions)
Figure 11. Neuroendocrine Carcinoma in Oncology Centres
Figure 12. Global Neuroendocrine Carcinoma Market: Oncology Centres (2017-2022) & ($ Millions)
Figure 13. Neuroendocrine Carcinoma in Ambulatory Surgery Centres
Figure 14. Global Neuroendocrine Carcinoma Market: Ambulatory Surgery Centres (2017-2022) & ($ Millions)
Figure 15. Global Neuroendocrine Carcinoma Market Size Market Share by Application in 2021
Figure 16. Global Neuroendocrine Carcinoma Revenue Market Share by Player in 2021
Figure 17. Global Neuroendocrine Carcinoma Market Size Market Share by Regions (2017-2022)
Figure 18. Americas Neuroendocrine Carcinoma Market Size 2017-2022 ($ Millions)
Figure 19. APAC Neuroendocrine Carcinoma Market Size 2017-2022 ($ Millions)
Figure 20. Europe Neuroendocrine Carcinoma Market Size 2017-2022 ($ Millions)
Figure 21. Middle East & Africa Neuroendocrine Carcinoma Market Size 2017-2022 ($ Millions)
Figure 22. Americas Neuroendocrine Carcinoma Value Market Share by Country in 2021
Figure 23. Americas Neuroendocrine Carcinoma Consumption Market Share by Type in 2021
Figure 24. Americas Neuroendocrine Carcinoma Market Size Market Share by Application in 2021
Figure 25. United States Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 26. Canada Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 27. Mexico Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 28. Brazil Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 29. APAC Neuroendocrine Carcinoma Market Size Market Share by Region in 2021
Figure 30. APAC Neuroendocrine Carcinoma Market Size Market Share by Application in 2021
Figure 31. China Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 32. Japan Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 33. Korea Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 34. Southeast Asia Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 35. India Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 36. Australia Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 37. Europe Neuroendocrine Carcinoma Market Size Market Share by Country in 2021
Figure 38. Europe Neuroendocrine Carcinoma Market Size Market Share by Type in 2021
Figure 39. Europe Neuroendocrine Carcinoma Market Size Market Share by Application in 2021
Figure 40. Germany Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 41. France Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 42. UK Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 43. Italy Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 44. Russia Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 45. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Region in 2021
Figure 46. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Type in 2021
Figure 47. Middle East & Africa Neuroendocrine Carcinoma Market Size Market Share by Application in 2021
Figure 48. Egypt Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 49. South Africa Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 50. Israel Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 51. Turkey Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 52. GCC Country Neuroendocrine Carcinoma Market Size Growth 2017-2022 ($ Millions)
Figure 53. Americas Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 54. APAC Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 55. Europe Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 56. Middle East & Africa Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 57. United States Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 58. Canada Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 59. Mexico Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 60. Brazil Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 61. China Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 62. Japan Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 63. Korea Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 64. Southeast Asia Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 65. India Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 66. Australia Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 67. Germany Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 68. France Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 69. UK Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 70. Italy Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 71. Russia Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 72. Spain Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 73. Egypt Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 74. South Africa Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 75. Israel Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 76. Turkey Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)
Figure 77. GCC Countries Neuroendocrine Carcinoma Market Size 2023-2028 ($ Millions)